Understanding molecular markers in recurrent oral squamous cell carcinoma treated with chemoradiation

被引:18
|
作者
Gupta, Seema [1 ]
Kushwaha, Vandana Singh [1 ]
Verma, Sandeep [1 ]
Khan, Huma [1 ]
Bhatt, M. L. B. [1 ]
Husain, Nuzhat [2 ]
Negi, Mahendra Pal Singh [3 ]
Bhosale, Vivek Vidyadhar [3 ]
Ghatak, Ashim [3 ]
机构
[1] King Georges Med Univ, Dept Radiotherapy, Lucknow, Uttar Pradesh, India
[2] RMLIMS, Depanment Pathol, Lucknow, Uttar Pradesh, India
[3] Cent Drug Res Inst, CSIR, Clin & Expt Med Div, Lucknow, Uttar Pradesh, India
来源
HELIYON | 2016年 / 2卷 / 12期
关键词
Medicine; Cancer Research; Oncology;
D O I
10.1016/j.heliyon.2016.e00206
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Introduction: Oral cancer accounts for approximately 2.1% of all cancers worldwide. In India, oral squamous cell carcinoma (OSCC) is the most common cancer with half a million new cases diagnosed every year. More than 50% of patients eventually develop local recurrence or metastasis usually within the first 2 years following completion of treatment. It is beneficial to analyze the prognostic significance of Cyclin D1, p53 and EGFR which are critical mediators in the pathogenesis of OSCC. The objective of this study was to assess the association of expression of these markers with recurrence and pattern of recurrence in OSCC patients undergoing chemoradiation. Materials and Methods: A Total 290 OSCC cases of locally advanced stage (III, IV) oral cancer with World Health Organization (W.H.O.) performance status of grade 0/1 in the year 2009-2012 were enrolled in the study. Treatment response was assessed according to W.H.O. criteria. Cyclin D1, EGFR and p53 expression in tumor tissue was estimated by immunohistochemical (IHC) method and quantified as percentage positive nuclei. Results: During the 2-years follow up, 56 (19.3%) patients recurred, out of which, 47 (83.9%) were locoregional and 9 (16.1%) distant sites. On correlating, chi(2) test showed significant (P < 0.05 or P < 0.01 or P < 0.001) association of marker expressions (Cyclin D1, EGFR and p53) with recurrence. The strong positive expressions of all three markers showed significant association with early time of recurrence. The multivariate logistic regression analysis showed significant (P < 0.05 or P < 0.01 or P < 0.001) association of recurrence with primary site, differentiation, Cyclin D1 and p53 expressions indicating these as an independent predictors of recurrence in OSCC. The Cyclin D1, EGFR and p53 expressions also showed significant (P < 0.001) poor survivals (OS, DFS and RFS) in patients with positive/strong positive expressions than negative expression suggesting their prognosis in OSCC. Conclusion: Our results signifies that tumors over expressing Cyclin D1, EGFR and p53 are resistant to chemoradiation and are associated with increased risk of locoregional recurrence and metastasis in OSCC patients undergoing chemoradiation.
引用
收藏
页数:35
相关论文
共 50 条
  • [31] Secreted protein markers in oral squamous cell carcinoma (OSCC)
    Mumtaz, Madiha
    Bijnsdorp, Irene, V
    Bottger, Franziska
    Piersma, Sander R.
    Pham, Thang, V
    Mumtaz, Samiullah
    Brakenhoff, Ruud H.
    Akhtar, M. Waheed
    Jimenez, Connie R.
    CLINICAL PROTEOMICS, 2022, 19 (01)
  • [32] Secreted protein markers in oral squamous cell carcinoma (OSCC)
    Madiha Mumtaz
    Irene V. Bijnsdorp
    Franziska Böttger
    Sander R. Piersma
    Thang V. Pham
    Samiullah Mumtaz
    Ruud H. Brakenhoff
    M. Waheed Akhtar
    Connie R. Jimenez
    Clinical Proteomics, 2022, 19
  • [33] ORAL SQUAMOUS CELL CARCINOMA: DIAGNOSTIC MARKERS AND PROGNOSTIC INDICATORS
    Lauritano, D.
    Lucchese, A.
    Contaldo, M.
    Serpico, R.
    Lo Muzio, L.
    Biolcati, F.
    Carinci, F.
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2016, 30 (02): : 169 - 176
  • [34] Understanding the molecular biology of anal squamous cell carcinoma
    Samuel, Robert J.
    Gilbert, Duncan C.
    INTERNATIONAL JOURNAL OF CANCER, 2024, 154 (03) : 410 - 411
  • [35] Complete response of recurrent oral squamous cell carcinoma treated with cetuximab in combination with radiotherapy: A case series
    Naruse, Tomofumi
    Furukawa, Kohei
    Miyoshi, Taro
    Morishita, Kota
    Otsuru, Mitsunobu
    Umeda, Masahiro
    ONCOLOGY LETTERS, 2022, 24 (06)
  • [36] Molecular markers predict outcome in squamous cell carcinoma of the head and neck after concomitant cisplatin-based chemoradiation
    van den Broek, Guido B.
    Wildeman, Maarten
    Rasch, Coen R. N.
    Armstrong, Nicola
    Schuuring, Ed
    Begg, Adrian C.
    Looijenga, Leendert H. J.
    Scheper, Rik
    van der Wal, Jacqueline E.
    Menkema, Lorian
    van Diest, Paul J.
    Balm, Alfons J. M.
    van Velthuysen, Marie-Louise F.
    van den Brekel, Michiel W. M.
    INTERNATIONAL JOURNAL OF CANCER, 2009, 124 (11) : 2643 - 2650
  • [37] Molecular Landscape of the Coagulome of Oral Squamous Cell Carcinoma
    Lottin, Marine
    Soudet, Simon
    Fercot, Julie
    Racine, Floriane
    Demagny, Julien
    Bettoni, Jeremie
    Chatelain, Denis
    Sevestre, Marie-Antoinette
    Mammeri, Youcef
    Lamuraglia, Michele
    Galmiche, Antoine
    Saidak, Zuzana
    CANCERS, 2022, 14 (02)
  • [38] Molecular biology of oral cavity squamous cell carcinoma
    Hsu, Phillip J.
    Yan, Kenneth
    Shi, Hailing
    Izumchenko, Evgeny
    Agrawal, Nishant
    ORAL ONCOLOGY, 2020, 102
  • [39] Molecular biology of oral cavity squamous cell carcinoma
    Kupferman, ME
    Myers, JN
    OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA, 2006, 39 (02) : 229 - +
  • [40] Molecular landscape of the coagulome of oral squamous cell carcinoma
    Lottin, M.
    Soudet, S.
    Sevestre, M. -A.
    Saidak, Z.
    Galmiche, A.
    THROMBOSIS RESEARCH, 2022, 213 : S34 - S35